Deerfield Management proposes to acquire Singular Genomics for $10 per share

Singular Genomics announced that it has received a non-binding proposal from Deerfield Management to acquire all of the company’s outstanding shares of common stock that are not already owned by Deerfield for $10.00 per share in cash. Deerfield, an existing stockholder of the company, indicated in its letter that it intends to invite other major stockholders and existing management to rollover their shares of common stock into the new company. The company’s board of directors previously formed a special committee of independent directors to evaluate and consider the company’s strategic alternatives, which would include the proposal submitted by Deerfield. There can be no assurance that any transaction will be consummated, whether involving Deerfield or any other party. The company and the special committee do not intend to comment further about Deerfield’s proposal unless and until the special committee deems further disclosure is appropriate.